Geode Capital Management’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.9M Buy
1,339,405
+322,063
+32% +$2.36M ﹤0.01% 2491
2026
Q1
$6.5M Buy
1,017,342
+22,997
+2% +$148K ﹤0.01% 2614
2025
Q4
$5.92M Buy
994,345
+10,823
+1% +$57.5K ﹤0.01% 2681
2025
Q3
$5.22M Buy
983,522
+11,848
+1% +$50.2K ﹤0.01% 2754
2025
Q2
$3.33M Buy
971,674
+16,218
+2% +$51.8K ﹤0.01% 2940
2025
Q1
$2.83M Buy
955,456
+36,021
+4% +$113K ﹤0.01% 2917
2024
Q4
$2.8M Buy
919,435
+2,068
+0.2% +$6.02K ﹤0.01% 3016
2024
Q3
$2.34M Sell
917,367
-32,779
-3% -$99.2K ﹤0.01% 3072
2024
Q2
$3.1M Buy
950,146
+497,175
+110% +$2.18M ﹤0.01% 2968
2024
Q1
$2.4M Buy
452,971
+8,925
+2% +$48.1K ﹤0.01% 3048
2023
Q4
$1.92M Buy
444,046
+18,531
+4% +$61.4K ﹤0.01% 3113
2023
Q3
$1.12M Buy
425,515
+29,119
+7% +$99.2K ﹤0.01% 3274
2023
Q2
$1.4M Buy
396,396
+4,774
+1% +$14.9K ﹤0.01% 3229
2023
Q1
$1.21M Buy
391,622
+10,711
+3% +$40.4K ﹤0.01% 3260
2022
Q4
$1.61M Buy
380,911
+6,245
+2% +$21.5K ﹤0.01% 3142
2022
Q3
$887K Buy
374,666
+4,575
+1% +$13.4K ﹤0.01% 3447
2022
Q2
$1.05M Sell
370,091
-229,323
-38% -$570K ﹤0.01% 3396
2022
Q1
$1.73M Sell
599,414
-37,878
-6% -$98K ﹤0.01% 3330
2021
Q4
$1.94M Buy
637,292
+30,141
+5% +$131K ﹤0.01% 3379
2021
Q3
$4.26M Sell
607,151
-13,975
-2% -$105K ﹤0.01% 3004
2021
Q2
$5.7M Buy
621,126
+18,738
+3% +$190K ﹤0.01% 2817
2021
Q1
$5.86M Buy
602,388
+76,049
+14% +$849K ﹤0.01% 2712
2020
Q4
$5.4M Sell
526,339
-11,546
-2% -$117K ﹤0.01% 2561
2020
Q3
$5.43M Buy
537,885
+10,870
+2% +$111K ﹤0.01% 2341
2020
Q2
$5.5M Buy
527,015
+54,578
+12% +$565K ﹤0.01% 2288
2020
Q1
$3.99M Sell
472,437
-93,606
-17% -$909K ﹤0.01% 2270
2019
Q4
$4.95M Buy
566,043
+163,303
+41% +$1.35M ﹤0.01% 2461
2019
Q3
$4.33M Buy
402,740
+8,128
+2% +$87.8K ﹤0.01% 2464
2019
Q2
$5.01M Buy
394,612
+25,692
+7% +$592K ﹤0.01% 2389
2019
Q1
$14.3M Buy
368,920
+33,051
+10% +$1.01M ﹤0.01% 1646
2018
Q4
$6.83M Buy
335,869
+11,840
+4% +$355K ﹤0.01% 2032
2018
Q3
$14.9M Buy
324,029
+19,396
+6% +$935K ﹤0.01% 1627
2018
Q2
$18M Buy
304,633
+6,276
+2% +$364K 0.01% 1434
2018
Q1
$20.3M Buy
298,357
+7,666
+3% +$574K 0.01% 1250
2017
Q4
$28.7M Buy
290,691
+7,772
+3% +$870K 0.01% 1004
2017
Q3
$33.9M Buy
282,919
+24,379
+9% +$2.27M 0.01% 886
2017
Q2
$22.6M Buy
258,540
+26,169
+11% +$1.46M 0.01% 1086
2017
Q1
$8.64M Buy
232,371
+34,190
+17% +$1.25M ﹤0.01% 1717
2016
Q4
$6.08M Buy
198,181
+26,490
+15% +$1.15M ﹤0.01% 1928
2016
Q3
$11.5M Buy
171,691
+24,741
+17% +$1.25M 0.01% 1402
2016
Q2
$4.38M Buy
146,950
+17,015
+13% +$532K ﹤0.01% 2007
2016
Q1
$3.82K Buy
129,935
+2,773
+2% +$125K ﹤0.01% 2045
2015
Q4
$9.97M Buy
127,162
+5,382
+4% +$422K 0.01% 1388
2015
Q3
$9.17M Sell
121,780
-4,256
-3% -$402K 0.01% 1405
2015
Q2
$14.7M Sell
126,036
-8,592
-6% -$1.56M 0.01% 1147
2015
Q1
$31.8M Buy
134,628
+11,233
+9% +$2.4M 0.02% 680
2014
Q4
$23.4M Buy
123,395
+760
+0.6% +$169K 0.01% 772
2014
Q3
$29.3M Buy
122,635
+5,370
+5% +$1.1M 0.02% 656
2014
Q2
$7.74M Buy
117,265
+364
+0.3% +$25.9K 0.01% 1496
2014
Q1
$12.2M Buy
116,901
+14,508
+14% +$1.71M 0.01% 1107
2013
Q4
$10.6M Buy
102,393
+1,299
+1% +$76.2K 0.01% 1146
2013
Q3
$5.42M Buy
101,094
+60,479
+149% +$3.26M ﹤0.01% 1499
2013
Q2
$1.8M Buy
+40,615
New +$1.43M ﹤0.01% 2109

Other funds holding PBYI

Geode Capital Management's PBYI Position: Q2 2026 in Review

Geode Capital Management increased its Puma Biotechnology (PBYI) stake by 32% in Q2 2026, buying an estimated $2.36M and bringing the position to 1,339,405 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

Geode Capital Management first reported a position in PBYI in Q2 2013 and has held it in 53 quarters since. The position peaked at $33.9M in Q3 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Geode Capital Management held 1,339,405 shares of Puma Biotechnology worth $10.9M as of Q2 2026.
  • Geode Capital Management bought 322,063 Puma Biotechnology shares in Q2 2026, an estimated $2.36M.
  • Puma Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2491 holding.
  • Geode Capital Management first reported a position in Puma Biotechnology in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Puma Biotechnology position peaked at $33.9M in Q3 2017.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.